Empagliflozin gets PBAC nod for HFpEF
The PBAC has recommended expanding the PBS listing for empagliflozin to include patients with chronic heart failure and a left ventricular ejection fraction above 40%.…
Tag: Pharmacology
Meet the doctor who changed the TGA’s mind on psychedelics
Professor David Nutt is unapologetic for advocating medical use of MDMA and psilocybin. A former drugs adviser to the UK Government, he has been researching psychedelics for almost two…
‘Limited’ semaglutide supplies on the way: TGA
Semaglutide will return to pharmacy shelves this month, but the TGA has warned not all patients previously prescribed the GLP-1 receptor agonist will be able…
Top psychiatrist has safety fears over TGA’s approval of psychedelics: ‘It’s a big jump’
A leading psychiatrist says the TGA jumped the gun in approving psychedelics for clinical use, saying questions around their efficacy and safety need to be…
‘Out of control’: RACGP says pharmacy guild president should consider standing down
Professor Trent Twomey should consider stepping down as president of the Pharmacy Guild of Australia after calling GPs “twits” and describing GP supervision of pharmacy…
Benzodiazepines a ‘high-risk’ treatment for amphetamine use disorder
Benzodiazepine treatment in patients with methamphetamine or amphetamine use disorder is linked to a higher risk of death and hospitalisation than other pharmacotherapies, research shows.…
Lab reports ‘vital’ amid rise in antibiotic-resistant shigella
GPs are being urged to order stool culture and antibiotic susceptibility testing when investigating suspected shigellosis amid a rise in multidrug-resistant cases. A health warning…
Pain management in chronic kidney disease
Joan is a 77-year-old woman with heart failure with preserved ejection fraction, orthostatic hypotension, central adiposity, and chronic kidney disease stage 3B without albuminuria. She…
Medicine reviews ‘crucial’ after bariatric surgery
GPs are being urged to consider the need to adjust the dose and formulation of oral medications for patients who have had bariatric surgery as…
New Alzheimer’s drug could be available next year, but are the risks worth the reward?
Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data…
